In the per-protocol population , 84 ( 85 % ) of 99 patients who completed eliglustat treatment and 44 ( 94 % ) of 47 patients who completed imiglucerase treatment met the composite primary endpoint ( between-group difference -88 % ; 95 % CI -176 to 42 ) .